629 related articles for article (PubMed ID: 26523062)
1. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
2. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
[TBL] [Abstract][Full Text] [Related]
3. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis.
Esposito M; Carubbi F; Giunta A; Alunno A; Giacomelli R; Fargnoli MC
Expert Rev Clin Immunol; 2020 Feb; 16(2):119-128. PubMed ID: 31917928
[No Abstract] [Full Text] [Related]
4. Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.
Deeks ED
BioDrugs; 2016 Dec; 30(6):607-617. PubMed ID: 27704400
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis.
Carubbi F; Fidanza R; Palmieri M; Ventura A; Tambone S; Cipriani P; Giacomelli R; Fargnoli MC
J Dermatolog Treat; 2020 Nov; 31(7):692-697. PubMed ID: 30963798
[No Abstract] [Full Text] [Related]
6. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
[TBL] [Abstract][Full Text] [Related]
8. New biologics for psoriasis and psoriatic arthritis.
Rozenblit M; Lebwohl M
Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
[TBL] [Abstract][Full Text] [Related]
9. Certolizumab pegol for the treatment of psoriatic arthritis.
Hansen RB; Kavanaugh A
Expert Rev Clin Immunol; 2015 Mar; 11(3):307-18. PubMed ID: 25651776
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life.
Dattola A; Mazzeo M; Di Stefano F; Manfreda V; Vollono L; Di Raimondo C; Di Matteo E; Bianchi L
Dermatol Ther; 2020 May; 33(3):e13409. PubMed ID: 32291887
[TBL] [Abstract][Full Text] [Related]
11. Profile of certolizumab and its potential in the treatment of psoriatic arthritis.
Chimenti MS; Saraceno R; Chiricozzi A; Giunta A; Chimenti S; Perricone R
Drug Des Devel Ther; 2013; 7():339-48. PubMed ID: 23620660
[TBL] [Abstract][Full Text] [Related]
12. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
Pasut G
BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
[TBL] [Abstract][Full Text] [Related]
13. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Gottlieb AB; Blauvelt A; Thaçi D; Leonardi CL; Poulin Y; Drew J; Peterson L; Arendt C; Burge D; Reich K
J Am Acad Dermatol; 2018 Aug; 79(2):302-314.e6. PubMed ID: 29660421
[TBL] [Abstract][Full Text] [Related]
14. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
Chatzidionysiou K; Kristensen LE; Eriksson J; Askling J; van Vollenhoven R;
Scand J Rheumatol; 2015; 44(6):431-7. PubMed ID: 26084325
[TBL] [Abstract][Full Text] [Related]
16. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.
Gehin JE; Goll GL; Warren DJ; Syversen SW; Sexton J; Strand EK; Kvien TK; Bolstad N; Lie E
Arthritis Res Ther; 2019 Nov; 21(1):256. PubMed ID: 31783773
[TBL] [Abstract][Full Text] [Related]
17. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
[TBL] [Abstract][Full Text] [Related]
18. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
[TBL] [Abstract][Full Text] [Related]
19. Biological agents in psoriatic arthritis.
Kocijan R; Muschitz C; Rech J
Wien Med Wochenschr; 2015 Jan; 165(1-2):36-9. PubMed ID: 25205184
[TBL] [Abstract][Full Text] [Related]
20. Psoriatic arthritis.
Durham LE; Taams LS; Kirkham BW
Br J Hosp Med (Lond); 2016 Jul; 77(7):C102-8. PubMed ID: 27388392
[No Abstract] [Full Text] [Related]
[Next] [New Search]